US FDA OK's Baxter's recombinant factor IX Rixubis
This article was originally published in Scrip
Executive Summary
With the FDA's approval on 27 June of Baxter's Rixubis, a recombinant factor IX, patients with hemophilia B now have a new option for responding to the hereditary bleeding disorder, which affects about 3,300 people in the US, mostly males.